Immuron Limited (IMRN)

AU — Healthcare Sector

Peers: NBTX XTLB SNOA EDSA VRNA ATHE IMMP

Automate Your Wheel Strategy on IMRN

With Tiblio's Option Bot, you can configure your own wheel strategy including IMRN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol IMRN
Rev/Share 1.3691
Book/Share 1.8113
PB 1.4894
Debt/Equity 0.0131
CurrentRatio 6.8
ROIC -0.6828

MktCap 15346507.7552
FreeCF/Share -1.7182
PFCF -1.5647
PE -1.5739
Debt/Assets 0.0111
DivYield 0
ROE -0.849

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 3
D/E Score 4

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Immuron partners with InvestorHub

IMRN
Published: August 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors.

image for news Immuron partners with InvestorHub

Immuron - FY25 global sales exceed projection, up 49% on prior year

IMRN
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior year June 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement …

image for news Immuron - FY25 global sales exceed projection, up 49% on prior year

About Immuron Limited (IMRN)

IPO Date 2017-06-09
Website https://www.immuron.com.au
Industry Biotechnology
CEO Steven George Lydeamore CPA,
Employees 7

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.